急性胰臟炎市場 - 全球產業規模、佔有率、趨勢、機會和預測，按治療、診斷、最終用戶、地區和競爭進行細分，2020 年至 2030 年

2024 年全球急性胰臟炎市場價值為 51 億美元，預計在預測期內將實現強勁成長，到 2030 年的複合年成長率為 5.59%。全球急性胰臟炎市場是醫療保健產業內一個充滿活力且不斷發展的產業，涵蓋急性胰臟炎（一種嚴重的胰臟發炎）的診斷、治療和管理。近年來，由於生活方式的改變、酒精消費的增加以及肥胖發病率的上升等多種因素，該市場經歷了顯著的成長和轉變，所有這些都導致​​了全球急性胰臟炎盛行率的上升。根據 NLM 2022 年 11 月的一篇文章，急性胰臟炎是美國最常見的胃腸道疾病，也是住院的主要原因。此外，2022 年 7 月 MedRxiv 的一篇文章報道稱，膽結石疾病導致約 220 萬次門診就診、110 萬次急診就診和 615,000 次出院。同一消息來源指出，女性比男性更容易罹患膽結石。這個市場的主要驅動力之一是人們對急性胰臟炎的認知和早期診斷不斷提高，這導致對影像學研究和血液檢查等診斷測試的需求激增，以準確識別和評估病情的嚴重程度。

主要市場促進因素

改變生活方式和風險因素

主要市場挑戰

治療費用高昂

主要市場趨勢

微創手術的進展

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：全球急性胰臟炎市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依治療（靜脈輸液、營養支持、止痛藥、內視鏡逆行性胰膽管攝影 (ERCP)、其他治療）
  • 透過診斷（影像檢查、實驗室檢查）
  • 按最終使用者（醫院和診所、門診護理中心、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖
  • 按治療
  • 根據診斷
  • 按最終用戶
  • 按地區

第5章：亞太地區急性胰臟炎市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按治療
  • 根據診斷
  • 按最終用戶
  • 按國家
• 亞太地區：國家分析
  • 中國
  • 印度
  • 澳洲
  • 日本
  • 韓國

第6章：歐洲急性胰臟炎市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 西班牙
  • 義大利
  • 英國

第7章：北美急性胰臟炎市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 墨西哥
  • 加拿大

第 8 章：南美洲急性胰臟炎市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第9章：中東和非洲急性胰臟炎市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 埃及

第10章：市場動態

• 驅動程式
• 挑戰

第 11 章：市場趨勢與發展

• 最新動態
• 產品發布
• 合併與收購

第 12 章：全球急性胰臟炎市場：SWOT 分析

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• SCM Lifescience
• GNT Pharma Co
• Baxter International Inc.
• B. Braun Melsungen AG
• General Electric Company
• Medtronic Plc
• Boston Scientific Corporation
• Fresenius Kabi USA
• McNeil Consumer Healthcare
• Sun BioPharma

第 15 章：策略建議

第16章調查會社について,免責事項

Global Acute Pancreatitis Market was valued at USD 5.10 billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 5.59% through 2030. The Global Acute Pancreatitis Market is a dynamic and evolving sector within the healthcare industry that encompasses the diagnosis, treatment, and management of acute pancreatitis, a severe inflammatory condition of the pancreas. This market has witnessed significant growth and transformation in recent years due to various factors, including changing lifestyle patterns, increasing alcohol consumption, and a rising incidence of obesity, all of which are contributing to the growing prevalence of acute pancreatitis worldwide. According to a November 2022 article by the NLM, acute pancreatitis is the most common gastrointestinal condition and the leading cause of hospitalization in the United States. Additionally, a July 2022 MedRxiv article reported that gallstone disease accounted for approximately 2.2 million ambulatory care visits, 1.1 million emergency department visits, and 615,000 hospital discharges. The same source noted that women are more likely to develop gallstones than men. One of the key drivers of this market is the increasing awareness and early diagnosis of acute pancreatitis, which has led to a surge in demand for diagnostic tests, such as imaging studies and blood tests, to accurately identify and assess the severity of the condition.

Key Market Drivers

Changing Lifestyle Patterns and Risk Factors

The global acute pancreatitis market is experiencing significant growth, in large part due to changing lifestyle patterns and the associated risk factors that are driving the increasing prevalence of this painful and potentially life-threatening condition. Modern lifestyles characterized by unhealthy dietary habits, high alcohol consumption, and a rising global obesity epidemic have created a perfect storm of risk factors that are contributing to the surge in acute pancreatitis cases worldwide. For instance, in December 2022, St. Jude Children's Research Hospital, in partnership with CalciMedica, Inc., initiated a Phase I/II clinical trial to evaluate the safety and effectiveness of CM4620 in children and young adults with asparaginase-induced acute pancreatitis. Also, in October 2022, Regeneron Pharmaceuticals initiated a Phase II clinical trial to assess the efficacy and safety of evinacumab in patients with severe hypertriglyceridemia to prevent recurrent acute pancreatitis.

Key Market Challenges

High Treatment Costs

One of the primary drivers of high treatment costs for acute pancreatitis is the need for hospitalization. Severe cases of acute pancreatitis often require extended stays in the hospital, where patients receive specialized care, including pain management, nutritional support, and monitoring for complications. These extended hospital stays can result in exorbitant medical bills, particularly in countries with private healthcare systems. Early and accurate diagnosis of acute pancreatitis is critical for effective management. However, diagnostic tests, such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and blood work, can be expensive. The cost of these diagnostic procedures can escalate the overall financial burden on patients and healthcare systems. In cases of severe acute pancreatitis, surgical interventions may be necessary to address complications like infected pancreatic necrosis or pseudocysts. Surgery, especially when performed laparoscopically or using minimally invasive techniques, can be costly and contribute significantly to the overall treatment expenses.

Key Market Trends

Advancements in Minimally Invasive Surgery

Advancements in minimally invasive surgical techniques have emerged as a pivotal trend in the global acute pancreatitis market, revolutionizing the treatment landscape for this severe pancreatic condition. Minimally invasive surgery (MIS), which includes procedures like laparoscopy and endoscopy, offers significant benefits such as reduced postoperative pain, shorter hospital stays, and faster patient recovery times. These advantages have not only improved patient outcomes but also contributed to the growth of the acute pancreatitis market in several ways.

One of the primary ways in which MIS is boosting the market is by enhancing patient comfort and overall satisfaction. Traditional open surgeries for acute pancreatitis often involve larger incisions and more extensive tissue disruption, leading to prolonged postoperative pain and recovery periods. In contrast, minimally invasive approaches involve smaller incisions, resulting in less pain, reduced scarring, and shorter hospitalization. This patient-centric focus has made MIS an attractive option for both patients and healthcare providers, driving its adoption and contributing to market growth.

Key Market Players

• SCM Lifescience
• GNT Pharma Co
• Baxter International Inc.
• B. Braun Melsungen AG
• General Electric Company
• Medtronic Plc
• Boston Scientific Corporation
• Fresenius Kabi USA
• McNeil Consumer Healthcare
• Sun BioPharma

Report Scope:

In this report, the Global Acute Pancreatitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acute Pancreatitis Market, By Treatment:

• Intravenous Fluid
• Nutritional Support
• Analgesics
• Endoscopic Retrograde Cholangiopancreatography (ERCP)
• Other treatments

Acute Pancreatitis Market, By Diagnosis:

• Imaging tests
• Laboratory Tests

Acute Pancreatitis Market, By End-User:

• Hospitals & Clinics
• Ambulatory care Centers
• Others

Acute Pancreatitis Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Acute Pancreatitis Market.

Available Customizations:

Global Acute Pancreatitis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Acute Pancreatitis Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Treatment (Intravenous Fluid, Nutritional Support, Analgesics, Endoscopic Retrograde Cholangiopancreatography (ERCP), Other treatments)
  • 4.2.2. By Diagnosis (Imaging tests, Laboratory Tests)
  • 4.2.3. By End-User (Hospitals & Clinics, Ambulatory care Centers, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Treatment
  • 4.3.2. By Diagnosis
  • 4.3.3. By End-User
  • 4.3.4. By Region

5. Asia Pacific Acute Pancreatitis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment
  • 5.2.2. By Diagnosis
  • 5.2.3. By End-User
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Acute Pancreatitis Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Treatment
      • 5.3.1.2.2. By Diagnosis
      • 5.3.1.2.3. By End-User
  • 5.3.2. India Acute Pancreatitis Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Treatment
      • 5.3.2.2.2. By Diagnosis
      • 5.3.2.2.3. By End-User
  • 5.3.3. Australia Acute Pancreatitis Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Treatment
      • 5.3.3.2.2. By Diagnosis
      • 5.3.3.2.3. By End-User
  • 5.3.4. Japan Acute Pancreatitis Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Treatment
      • 5.3.4.2.2. By Diagnosis
      • 5.3.4.2.3. By End-User
  • 5.3.5. South Korea Acute Pancreatitis Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Treatment
      • 5.3.5.2.2. By Diagnosis
      • 5.3.5.2.3. By End-User

6. Europe Acute Pancreatitis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Diagnosis
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Acute Pancreatitis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Diagnosis
      • 6.3.1.2.3. By End-User
  • 6.3.2. Germany Acute Pancreatitis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Diagnosis
      • 6.3.2.2.3. By End-User
  • 6.3.3. Spain Acute Pancreatitis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Diagnosis
      • 6.3.3.2.3. By End-User
  • 6.3.4. Italy Acute Pancreatitis Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Treatment
      • 6.3.4.2.2. By Diagnosis
      • 6.3.4.2.3. By End-User
  • 6.3.5. United Kingdom Acute Pancreatitis Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Treatment
      • 6.3.5.2.2. By Diagnosis
      • 6.3.5.2.3. By End-User

7. North America Acute Pancreatitis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Diagnosis
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Acute Pancreatitis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Diagnosis
      • 7.3.1.2.3. By End-User
  • 7.3.2. Mexico Acute Pancreatitis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Diagnosis
      • 7.3.2.2.3. By End-User
  • 7.3.3. Canada Acute Pancreatitis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Diagnosis
      • 7.3.3.2.3. By End-User

8. South America Acute Pancreatitis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Diagnosis
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Acute Pancreatitis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Diagnosis
      • 8.3.1.2.3. By End-User
  • 8.3.2. Argentina Acute Pancreatitis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Diagnosis
      • 8.3.2.2.3. By End-User
  • 8.3.3. Colombia Acute Pancreatitis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Diagnosis
      • 8.3.3.2.3. By End-User

9. Middle East and Africa Acute Pancreatitis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Diagnosis
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Acute Pancreatitis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Diagnosis
      • 9.3.1.2.3. By End-User
  • 9.3.2. Saudi Arabia Acute Pancreatitis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Diagnosis
      • 9.3.2.2.3. By End-User
  • 9.3.3. UAE Acute Pancreatitis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Diagnosis
      • 9.3.3.2.3. By End-User
  • 9.3.4. Egypt Acute Pancreatitis Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Treatment
      • 9.3.4.2.2. By Diagnosis
      • 9.3.4.2.3. By End-User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Acute Pancreatitis Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. SCM Lifescience
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. GNT Pharma Co
• 14.3. Baxter International Inc.
• 14.4. B. Braun Melsungen AG
• 14.5. General Electric Company
• 14.6. Medtronic Plc
• 14.7. Boston Scientific Corporation
• 14.8. Fresenius Kabi USA
• 14.9. McNeil Consumer Healthcare
• 14.10. Sun BioPharma

15. Strategic Recommendations

16. About Us & Disclaimer